The difference between ixazomib and bortezomib

Ixazomib and bortezomib, both proteasome inhibitors, are important drugs in anti-cancer treatment. They act on cancer cells through different mechanisms and exhibit their own unique therapeutic effects.

Ixazomib, an oral proteasome inhibitor, occupies a place in the treatment of multiple myeloma due to its high selectivity and significant therapeutic effect. It regulates the stability of immunoglobulins and fights the proliferation of tumor cells, providing a new treatment option for patients with relapsed or refractory mantle cell lymphoma and multiple myeloma. Especially for patients with multiple myeloma who have received at least first-line treatment, the treatment regimen of ixazomib combined with lenalidomide and dexamethasone can significantly extend the patient's survival and improve their quality of life.

Bortezomib inhibits cell proliferation by interfering with proteasome function, thus exerting anti-cancer effects. Its indications are broader, not limited to multiple myeloma, but also include hematological diseases such as mantle cell lymphoma. Bortezomib treatment options are diverse and can be tailored to the patient's specific circumstances. However, compared with ixazomib, bortezomib may cause more toxic side effects, such as peripheral neuropathy, anemia, etc., and patients need to pay close attention during use.

In general, there are obvious differences between ixazomib and bortezomib in terms of mechanism of action, indications, and toxic and side effects. The choice of which drug to treat requires a comprehensive consideration based on the patient's specific situation, the severity of the disease, and the doctor's professional advice. At the same time, with the deepening of research and the accumulation of clinical data, we believe that the application of these two drugs in anti-cancer treatment will be more precise and effective.